ClinicalTrials.gg

Program

IBI3033

A development code.

Its studies are mostly in Dermatitis, Atopic, led by Innovent Biologics.

Furthest: phase 1, since Dec 16, 20253 company-led studies, 3 open or runningNext primary completion: Feb 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics33 open or runningphase 1since Dec 16, 2025Dec 16, 2025Feb 10, 2027phase 1 · NCT07549984

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07311226 · 32 enrolled · China
  2. Feb 27, 2026Phase 1 study in Healthy ParticipantsNCT07456839 · 8 enrolled · China
  3. Apr 19, 2026Phase 1 study in Dermatitis, AtopicNCT07549984 · 16 planned · China

Ahead

  1. Feb 10, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07549984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07549984Dermatitis, Atopic · China1Not yet recruitingFeb 10, 202716
NCT07456839Healthy Participants · China1Active, not recruitingSep 30, 20268
NCT07311226Healthy Participants · China1Active, not recruitingJun 30, 202632

How it is read

Names in the registry

  • “IBI3033”, 3 entries

Codes read as this program: IBI3033.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.